CN113226323B - 马德辛衍生化合物、组合物及其用于治疗癌症的用途 - Google Patents

马德辛衍生化合物、组合物及其用于治疗癌症的用途 Download PDF

Info

Publication number
CN113226323B
CN113226323B CN201980074485.XA CN201980074485A CN113226323B CN 113226323 B CN113226323 B CN 113226323B CN 201980074485 A CN201980074485 A CN 201980074485A CN 113226323 B CN113226323 B CN 113226323B
Authority
CN
China
Prior art keywords
cancer
compound
subject
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980074485.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113226323A (zh
Inventor
塞巴斯蒂安·阿普谢
穆阿德·阿拉米
罗曼·达里格朗德
萨米尔·梅萨奥迪
瓦莱丽·萨尔格斯
扎菲亚里索亚·多罗·伦科
埃克斯佩迪特·延-庞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Thackeray, University of
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Paris Thackeray, University of
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Thackeray, University of, Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Paris Thackeray, University of
Publication of CN113226323A publication Critical patent/CN113226323A/zh
Application granted granted Critical
Publication of CN113226323B publication Critical patent/CN113226323B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980074485.XA 2018-11-15 2019-11-15 马德辛衍生化合物、组合物及其用于治疗癌症的用途 Active CN113226323B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306499.7 2018-11-15
EP18306499 2018-11-15
PCT/EP2019/081516 WO2020099650A1 (en) 2018-11-15 2019-11-15 Madrasin-derivative compounds, composition and uses thereof for treating cancer

Publications (2)

Publication Number Publication Date
CN113226323A CN113226323A (zh) 2021-08-06
CN113226323B true CN113226323B (zh) 2024-12-31

Family

ID=64564768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074485.XA Active CN113226323B (zh) 2018-11-15 2019-11-15 马德辛衍生化合物、组合物及其用于治疗癌症的用途

Country Status (9)

Country Link
US (1) US12213978B2 (https=)
EP (1) EP3880205B1 (https=)
JP (1) JP7636322B2 (https=)
KR (1) KR20210124187A (https=)
CN (1) CN113226323B (https=)
AU (1) AU2019379310B2 (https=)
CA (1) CA3118222A1 (https=)
IL (1) IL282692B2 (https=)
WO (1) WO2020099650A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243519A1 (en) * 2019-05-29 2020-12-03 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021231908A2 (en) * 2020-05-15 2021-11-18 Fred Hutchinson Cancer Research Center Compositions and methods for enhancing cancer immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165495A1 (en) * 2016-03-25 2017-09-28 University Of Maryland, Baltimore County Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012007872A (es) * 2010-01-06 2012-10-03 Joseph P Errico Metodos y composiciones de desarrollo de farmacos dirigidos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165495A1 (en) * 2016-03-25 2017-09-28 University Of Maryland, Baltimore County Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy;Maayan Salton等;《Tends in Molecular Medicine》;第22卷(第1期);28-37 *

Also Published As

Publication number Publication date
JP7636322B2 (ja) 2025-02-26
US20220047597A1 (en) 2022-02-17
IL282692B2 (en) 2024-09-01
JP2022512874A (ja) 2022-02-07
EP3880205C0 (en) 2023-08-30
WO2020099650A1 (en) 2020-05-22
CN113226323A (zh) 2021-08-06
IL282692B1 (en) 2024-05-01
US12213978B2 (en) 2025-02-04
KR20210124187A (ko) 2021-10-14
AU2019379310A1 (en) 2021-06-10
IL282692A (en) 2021-06-30
AU2019379310B2 (en) 2025-02-20
CA3118222A1 (en) 2020-05-22
EP3880205A1 (en) 2021-09-22
EP3880205B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
WO2016204193A1 (ja) 抗がん剤
AU2018204591A1 (en) Small molecule enhancer for dendritic cell cancer vaccines
UA124748C2 (uk) N-заміщені індольні похідні
US20210379106A1 (en) Oxabicycloheptanes for enhancing car t cell function
CN113226323B (zh) 马德辛衍生化合物、组合物及其用于治疗癌症的用途
TW201818934A (zh) Ｍｄｍ２抑制劑與ｄｎａ甲基轉移酶抑制劑之倂用治療法
CN110891944B (zh) 用于治疗癌症的化合物、组合物及其用途
CN111867598A (zh) 肿瘤免疫赋活剂
CN115227695A (zh) 包含靶向治疗剂的联合疗法
CA3059270C (en) Compounds, composition and uses thereof fortreating cancer
KR20250078360A (ko) 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
JP2024503513A (ja) がんを処置するための併用療法スケジュール
CN114126624A (zh) Hsp90结合缀合物及其联合疗法
HK40023858A (en) Combination therapies comprising targeted therapeutics
HK1229708A1 (en) Small molecule enhancer for dendritic cell cancer vaccines
HK1229708A (en) Small molecule enhancer for dendritic cell cancer vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant